Companion Diagnostics Market

Companion Diagnostics Market registered a revenue of USD 6.7 billion in 2022 and is projected to reach USD 20.6 billion in 2030, growing at a very high CAGR of 15.1% during the forecast period.

To have an edge over the competition by knowing the market dynamics and current trends of “Companion Diagnostics Market”, request for Sample Report here

Major Companion Diagnostics Market Drivers

Companion diagnostics play an important role in the effective and safe use of a corresponding drug. Greater patient access and better clinical utility evidence have facilitated the acceleration of diagnostics in the medical world. There is an emerging consensus that diagnostics appear to offer a set of tools, which helps the biopharmaceutical players address and overcome the problems, which has drastically changed the landscape of the market. Furthermore, strategic initiatives by the key players in the market have helped develop the novel techniques that have pushed the pace of market. For instance, in 2021, INOVIO pharmaceuticals inc. and QIAGEN have strategically collaborated for the development novel diagnostic for immunotherapy in HPV-associated cervical dysplasia. The collaboration aims to utilize QIAGEN’s bioinformatic expertise to further the predictive power of the biomarker signature developed by INOVIO, which is expected to shift the paddles for the market.

In addition, the rising adoption and availability of personalized medicines for diseases like Brineura, for the treatment of CLN2 type batten disease, Rydapt for acute myeloid leukaemia, is likely to continue to pave the road towards growth, which can be an opportunity for the market.

Restraint in the Companion Diagnostics Market

However, high cost in the advancement and infrastructure for research and development is the factor that is hampering the market.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Offering – Segment Analysis

Based on the offering, the product segment is anticipated to dominate the market over the forecast period. This is due to the emergence of highly sensitive technologies such as NGS for cancer diagnosis. Leading companies such as Roche, Illumina and ThermoFisher Scientific are expected to see lucrative growth opportunities in the coming decades due to increased use of cancer diagnostic equipment due to the rising disease burden.

Disease Type – Segment Analysis

Based on the disease type, NSCLC segment is likely to dominate the market over the forecast period. This is due to the high incidence rate of NSCLC coupled with a rise in the development of oncology diagnostic tests for the disease. For instance, In May 2020, the FDA approved FoundationOne CDx assay for use with Capmatinib to treat metastatic NSCLC, which has contributed to the growth of the market.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Regional – Segment Analysis:

Based on the region, North America is expected to dominate the market over the forecast period. Funding and grants provided by bodies, such as the National Cancer Institute (NCI), to accelerate precision therapy development which has positively influenced the market. Effective regulations pertaining to the approval of oncology companion diagnostic tests for cancer coupled with accelerated R&D for integrated and personalized medicine in the U.S. have driven the market.

Top Market Players

Various notable players operating in the market, include, Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories., Abbott, Myriad Genetics, Inc., BioMérieux SA, Invivoscribe, Inc., among others. 

Key Developments:

• • In 2020, Thermo Fisher Scientific Inc. and Agios Pharmaceuticals strategic partnership was made to codevelop a second companion diagnostics platform for oncology.

Segments covered in the Report:

The global companion diagnostics market has been segmented based on offering, technology, disease type, end-use and regions. Based on offering, the market is segmented into product and service. Based on technology, the market is segmented into PCR, NGS, IHC, FISH and others. Based on disease type, the market is segmented into breast cancer, NSCLC, melanoma, colorectal and others. Based on end-use the market is segmented into hospitals, pathology and diagnostic labs, academic medical center and others. 

For detailed scope of the “Companion Diagnostics Market” report request a Sample Copy of the report

Report Coverage	Details
Market Revenues (2022)	USD 6.7 billion
Market Base Year	2022
Market Forecast Year	2023-2030
Base Year & Forecast Units	Revenues (USD Billion)
Market Segment	By Offering, By Technology, By Disease Type, By End-Use, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories., Abbott, Myriad Genetics, Inc., BioMérieux SA, Invivoscribe, Inc., among others; a total of 10 companies covered.
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

Market Segmentation

Global Companion Diagnostics Market by Offering

• • Solution
  • Service

Global Companion Diagnostics Market by Technology

• • PCR
  • NGS
  • IHC
  • FISH
  • Others

Global Companion Diagnostics Market by Disease Type

• • Breast Cancer
  • NSCLC
  • Melanoma
  • Colorectal
  • Others

Global Companion Diagnostics Market by End-Use

• • Hospitals
  • Pathology and Diagnostic Labs
  • Academic Medical Center
  • Others

Global Companion Diagnostics Market by Region

• • North America Companion Diagnostics Market (Option 1: As a part of the free 25% customization)

    • By Offering
    • By Technology
    • By Disease Type
    • By End-Use
    • US Market All-Up
    • Canada Market All-Up

  • Europe Companion Diagnostics Market (Option 2: As a part of the free 25% customization)

    • By Offering
    • By Technology
    • By Disease Type
    • By End-Use
    • UK Market All-Up
    • Germany Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up

  • Asia-Pacific Companion Diagnostics Market (Option 3: As a part of the free 25% customization)

    • By Offering
    • By Technology
    • By Disease Type
    • By End-Use
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up

  • RoW Companion Diagnostics Market (Option 4: As a part of the free 25% customization)

    • By Offering
    • By Technology
    • By Disease Type
    • By End-Use
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Major Players Operating in the Companion Diagnostics (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Hoffmann-La Roche Ltd.
  • ARUP Laboratories.
  • Abbott
  • Myriad Genetics, Inc.
  • BioMérieux SA
  • Invivoscribe, Inc.